At Catalyst Pharmaceuticals, we understand that receiving a rare disease diagnosis can be extremely difficult. Often patients feel isolated and hopeless. That’s why we believe that, when you’re battling a rare disease—it’s all about the company you keep.
Our company is committed to developing novel, safe, and efficacious therapies that will improve the lives of people with rare and ultra-rare diseases.
Corporate Citizenship
Social responsibility is at the heart of everything we do
A Singular Mission
To improve the lives of patients with rare and ultra-rare diseases
Partnering With Patients
Empowering patients to take an active role in their health care
Cutting-Edge Science
The innovation behind a breakthrough
News & Events
FDA Approves Firdapse® (amifampridine) for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)
CORAL GABLES, Fla., November 29, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic…
read more
Catalyst Pharmaceuticals Expands Commercial Leadership Team
Augments Medical Affairs Team with 3 Additional Medical Science Liaisons CORAL GABLES, Fla., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing...
read more
Patients and Biopharma: Trusted Partners in Fighting Rare Diseases
Significant advances have been made in fighting rare diseases over the past decades. In the 10 years prior to the passage of the Orphan Drug Act in 1983, fewer than 10 drugs for rare diseases were approved by the U.S. FDA. Since then, an estimated 400 rare-disease...
read more
Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer
CORAL GABLES, Fla., June 13, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic...
read more
Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse® (Amifampridine Phosphate) for Lambert-Eaton Myasthenic Syndrome
--PDUFA Date Set for November 28, 2018 CORAL GABLES, Fla., May 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with...
read more
Catalyst Neuromuscular Connections
Click here to download this issue as a PDF.
read more